Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 3, 1996, Pages 776-779

  Trautmann, M ^a   Ruhnke, M ^b   Borner, K ^b   Wagner, J ^b   Koeppe, P ^b  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; SPARFLOXACIN;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; STREPTOCOCCUS PNEUMONIAE;

EID: 0030053609     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.3.776     Document Type: Article

References (40)

1. Aubier, M., J. Garau, P. Geslin, C. Grassi, J. Hosie, G. Huchon, N. Legakis, H. Lode, C. Regamey, S. Segev, R. Verster, and W. J. Wijnands. 1994. Efficacy of sparfloxacin (S) in The treatment of documented pneumococcal community-acquired pneumonia (CAP). A meta-analysis of two comparative studies. abstr. no. 460. 6th International Congress for Infectious Diseases, Prague, Czech Republic.
2. Ausina, V., P. Coll, M. Sambeat, I. Puig, M. J. Condom, M. Luquin, F. Ballester, and G. Prats. 1988. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur. J. Clin. Microbiol Infect. Dis. 7:343-347.
3. Barry, B., P. Gehanno, M. Blumen, and J. Boucot. 1994. Clinical outcome of acute otitis media caused by pneumococci with decreased susceptibility to penicillin. Scand. J. Infect. Dis. 26:446-452.
4. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance Antimicrob. Agents Chemother. 31:1054-1060
5. Borner, K., E. Borner, and H. Lode. 1992. Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. J. Chromatogr. 579:285-289.
6. Cantón, E., J. Permán, M. T. Jimenez, M. S. Ramón, and M. Gobernado. 1992. In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. 36:558-565.
7. Chin, N. X., J. W. Gu, K. W. Yu, Y. X. Zhang, and H, C. Neu. 1991. In vitro activity of sparfloxacin. Antimicrob. Agents Chemother. 35:567-571.
8. Echols, R., M. P. Weinstein, B. O'Keeffe, A. Shah, and A. H. Heller. 1994. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin J Antimicrob. Chemother. 33: 111-118.
9. European Study Group for Antimicrobial Breakpoints. 1994 Breakpoint determination: sparfloxacin. Eur J. Clin. Microbiol. Infect. Dis. 13:283-284.
10. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1981.
11. Friedland, I. R., and G. H. McCracken, Jr. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J Med. 331:377-382
12. Fuchs, P. C., A. L. Barry, M. A. Pfaller, S. D. Allen, and E. II. Gerlach. 1991. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960. and PD 131.628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob. Agents Chemother. 35:764-766.
13. Gibaldi, M. 1991. Biopharmaceutics and clinical pharmacokinetics, 4th ed. p. 14-16. Lea & Febiger, Philadelphia.
14. Goldstein, F. W., and J. Garau. 1994. Resistant pneumococci: a renewed threat in respiratory infections. Scand. J. Infect. Dis. Suppl. 93:55-62.
15. Hackbarth, C. J., H. F. Chambers, and M. A. Sande. 1986 Serum bactericidal titer as a predictor of outcome in endocarditis. Eur J Clin. Microbiol. 5:93-97.
16. Hammerschlag, M. R., C. L. Hyman, and P. M. Robin. 1992. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 36:682-683.
17. Honeybourne, D., I. Greaves, D. R. Baldwin, J. M. Andrews, M. Harris, and R. Wise. 1994. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int. J. Antimicrob. Agents 4:151-155
18. Johnson, J. H., M. A. Cooper, J. M. Andrews, and R. Wise. 1992. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother. 36:2444-2446.
19. Kaku, M., K. Ishida, K. Irifune, R. Mizukane, H. Takemura, R. Yoshida, H. Tanaka, T. Usui, K. Tomono, N. Suyama, H. Koga, S. Kohno, and K. Hara. 1994. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 38:738-741.
20. Klastersky, J., Daneau, D., G. Swings, and D. Weerts. 1974. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J. Infect Dis. 129:187-193
21. Koeppe, P., and C. Hamann. 1980 A program for non-linear regression analysis to be used on desk-top computers. Comput Progr. Biomed. 12:121-128.
22. Lee, B. L., A. M. Padula, R. C. Kimbrough et al. 1991. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325:520-521.
23. Liñares, J., R. Pallares, T. Alonso, J. L. Perez, J. Ayats, F. Gudiol, P. F. Viladrich, and R. Martin. 1992. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin. Infect. Dis. 15:99-105.
24. Malmborg, A. S., and S. Ahlén. 1993. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory pathogens. Chemotherapy 39:32-35.
25. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 3rd edition; approved standard, p. 17-20. National Committee for Clinical Laboratory Standards document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. Oethinger, M., B. Rothmaier, W. R. Heizmann, and M. Trautmann. 1995. Comparative in vitro activity of sparfloxacin and other antimicrobial agents against clinical isolates of Streptococcus pneumoniae. Staphylococcus aureus. Moraxella catarrhalis, and Haemophilus influenzae, abstr. 679. Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria.
27. Pallares, R., F. Gudiol, J. Liñares, J. Ariza, G. Rufi, L. Murgui, J. Dorca, and P. F. Viladrich. 1987. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N. Engl. J. Med. 317:18-22.
28. Pérer-Trallero, E., J. M. Garcia-Arenzana, J. A. Jimenez, and A. Peris. 1990. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Bur. J. Clin. Microbiol. Infect Dis. 9:905-906.
29. Platt, R., S. L. Ehrlich, J. Afarian, T. F. O'Brian, J. E. Pennington, and E. II. Kass. 1991. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: Influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy. Antimicrob. Agents Chemother. 20:351-355.
30. Prober, C. G., and A. S. Yeager. 1979. Use of the serum bactericidal titer to assess the adequacy of oral antibiotic therapy in the treatment of acute hematogenous osteomyelitis. J. Pediatr. 95:131-135.
31. Reller, L. B., and C. W. Stratton. 1977. Serum dilution test for bactericidal activity. II Standardization and correlation with antimicrobial assays and susceptibility tests. J. Infect. Dis. 136:196-203.
32. Rowland, M., and T. N. Tozer. 1995. Clinical pharmacokinetics. concepts and applications, third ed. Lea & Febiger, Philadelphia.
33. Sanchez, C., R. Armengod, J. Lite, I. Mir, and J. Garau. 1992. Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet 339:988. (Letter.)
34. Schwarz, G. 1978. Estimating the dimension of a model Ann Statistics 6:461-464.
35. Sculier, J. P., and J. Klastersky. 1984. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia Am J. Med. 78:262-269.
36. Shimada, J., T. Nogita, and Y. Ishibashi. 1993. Clinical pharmacokinetics of sparfloxacin. Clin. Pharmacokinet. 25:358-369.
37. Simor, A. E., S. A. Fuller, and D. E. Low. 1990. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens. Antimicrob. Agents Chemother. 34:2283-2286.
38. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1994. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob. Agents Chemother. 38:898-900.
39. Standiford, H. C., and B. A. Tatem. 1986. Technical aspects and clinical correlations of the serum bactericidal test. Eur. J. Clin. Microbiol. 5:79-87.
40. Weinstein, M. P., C. W. Stratton, A. Ackley, H. B. Hawley, P. A. Robinson, B. D. Fisher, D. V. Alcid, D. S. Stephens, and L. B. Reller. 1985. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am. J. Med. 78:262-268.